

1 Full title: Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal

2 Vaccines in Adults

3 Short title: The Efficacy and Effectiveness of Pneumococcal Vaccines in Adults

4 Authors: Jennifer L Farrar, Lana Childs, Mahamoudou Ouattara, Fahmina Akhter, Amadea Britton,

5 Tamara Pilishvili, Miwako Kobayashi

6 Affiliations: Respiratory Diseases Branch, U.S. Centers for Disease Control and Prevention, Atlanta,

7 Georgia, USA; CDC Foundation, Atlanta, Georgia, USA

8 Corresponding author: Jennifer L Farrar, [ih4@cdc.gov](mailto:ih4@cdc.gov)

9

## 10 Abstract

11 The 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide  
12 vaccine (PPSV23) were previously recommended for adults in the United States. To help inform  
13 discussions on recently licensed 15- and 20-valent pneumococcal vaccine use among adults, we  
14 conducted a systematic review of PCV13 and PPSV23 efficacy or effectiveness. We conducted a search  
15 on PCV13 and PPSV23 efficacy or effectiveness (VE) studies against vaccine type (VT) invasive  
16 pneumococcal disease (IPD) and VT-pneumococcal pneumonia in adults. Nineteen studies were  
17 included: 13 on VT-IPD (four on PCV13, nine on PPSV23) and eight on VT- pneumococcal pneumonia  
18 (three on PCV13, four on PPSV23, one on PCV13 and PPSV23). One randomized-controlled trial (RCT)  
19 evaluated PCV13 and observed an efficacy of 75% and 45% against VT-IPD and VT-pneumococcal  
20 pneumonia, respectively. No RCTs reported PPSV23 efficacy. PCV13 effectiveness estimates against VT-  
21 IPD ranged from 47% to 68%. Pooled PPSV23 effectiveness against VT-IPD was 45% (95% CI: 37%, 51%;  
22  $I^2=0\%$ ). PCV13 VE estimates against VT-pneumonia ranged from -2 to 46%. Pooled PPSV23 VE against  
23 VT-pneumococcal pneumonia was 18% (95% CI: -4%, 35%;  $I^2=0\%$ ). Evidence suggests PCV13 and PPSV23  
24 are effective against VT-IPD and VT-pneumococcal pneumonia in adults; this was used to inform PCV15  
25 and PCV20 policy decisions.

26

27 **Keywords:** pneumococcal vaccine, invasive pneumococcal disease, pneumonia, adults, vaccine  
28 effectiveness

29

## 30 Introduction

31 The bacteria, *Streptococcus pneumoniae*, are responsible for a substantial proportion of disease burden  
32 in adults, especially among older adults and those with immunocompromising conditions. Invasive  
33 pneumococcal disease (IPD) incidence among U.S. adults aged  $\geq 65$  years was 24 per 100,000 during

34 2018–2019 (ABCs surveillance), and disease caused by serotype 3, a serotype included in vaccines to  
35 prevent pneumococcal disease, is the most common vaccine serotype causing IPD in adults [1, 2]. In a  
36 2016 study of U.S. adults hospitalized with radiologically confirmed community-acquired pneumonia,  
37 8.2% (n=520) of adults  $\geq 65$  years had *S. pneumoniae* detected by urine antigen; of these, 269 (51.7%)  
38 were serotypes included in the 13-valent pneumococcal conjugate vaccine (PCV13) [2].

39 Until recently, there were two pneumococcal vaccines recommended for use in U.S. adults to prevent  
40 disease caused by *S. pneumoniae*. Since 2012, PCV13 has been recommended for use in adults aged  $\geq 19$   
41 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks,  
42 or cochlear implants. The 23-valent pneumococcal polysaccharide vaccine, PPSV23, has been in use  
43 since 1984, and, until recently, was recommended for all adults aged  $\geq 65$  years and adults aged  $\geq 19$   
44 years with immunocompromising conditions, functional or anatomic asplenia, or immunocompetent  
45 conditions [3]. While studies have shown that PPSV23 is effective against VTIPD, data on effectiveness of  
46 PPSV23 against nonbacteremic pneumococcal pneumonia have been inconsistent [4]. In contrast, a  
47 large randomized controlled trial (RCT) in adults aged  $\geq 65$  years in the Netherlands showed that PCV13  
48 is effective against VT-IPD and VT- nonbacteremic pneumococcal pneumonia [5]. Data from this study  
49 supported the 2014 recommendation for routine PCV13 use for all adults aged  $\geq 65$  years in the United  
50 States [4]; however, additional years of data showed that there was limited population-level impact of  
51 routine PCV13 use in adults of this age group, likely due to the already realized indirect effects from  
52 PCV13 use in children. As a result, in 2019, PCV13 was no longer routinely recommended for adults aged  
53  $\geq 65$  years without immunocompromising conditions, cerebrospinal fluid leaks, or cochlear implants and  
54 instead recommended based on shared clinical decision-making [6].

55 In 2021, two new pneumococcal conjugate vaccines (PCVs) were licensed for use in the United States:  
56 15-valent PCV (PCV15) and 20-valent PCV (PCV20) [7, 8]. PCV15 contains all 13 serotypes included in

57 PCV13 plus serotypes 22F and 33F. In the United States, serotypes 22F and 33F accounted for 15% of IPD  
58 in adults aged  $\geq 65$  years and 13% of IPD in adults aged 19 through 64 years with certain underlying  
59 medical conditions during 2018–2019 [9]. PCV20 contains all serotypes included in PCV13 and PCV15  
60 (22F and 33F) as well as serotypes 8, 10A, 11A, 12F, and 15B. In the United States, these additional  
61 serotypes accounted for 27% of IPD in adults aged  $\geq 65$  years and 28% of IPD in adults with certain  
62 underlying medical conditions in 2018–2019 [9]. Phase II/III RCTs for PCV15 [10–12] and PCV20 [13, 14]  
63 showed immunogenicity and safety comparable with PCV13 or PPSV23; similar findings were observed  
64 for PCV15 use among adults with certain underlying medical conditions [15, 16].

65 A review of PCV13 and PPSV23 effectiveness against clinical outcomes was necessary for a few reasons:  
66 first, we expect that PCV15 and PCV20 will have similar effectiveness as PCV13 and PPSV23 and given  
67 these new vaccines were licensed based on safety and immunogenicity data only, this review would  
68 provide a comprehensive summary of overall pneumococcal vaccine effectiveness against clinical  
69 outcomes in adults. Second, PPSV23 was likely to be part of the new recommendations and previous  
70 literature found inconsistent evidence regarding PPSV23 effectiveness against non-bacteremic  
71 pneumococcal pneumonia. Lastly, PCV13 would be used as a comparator vaccine to the newer higher  
72 valent conjugate vaccines under discussion and a full review of PCV13 effectiveness against clinical  
73 outcomes was necessary. Therefore, we conducted a systematic review of literature on the efficacy or  
74 effectiveness of PCV13 and PPSV23 against VT-IPD and VT-pneumococcal pneumonia in adults to help  
75 inform the U.S. Advisory Committee on Immunization Practices' (ACIP) discussions on the use of PCV15  
76 and PCV20 among adults.

## 77 **Methods**

### 78 *Literature search*

79 In 2019, the Norwegian Public Health Institute (NIPH) conducted a systematic review of literature on  
80 pneumococcal vaccine effectiveness in adults for the World Health Organization’s Strategic Advisory  
81 Group of Experts [17]. We utilized the same search strategy (Appendix 1) and updated the search  
82 timeline to update the summary of evidence on pneumococcal vaccine efficacy or effectiveness on  
83 pneumococcal disease and mortality in adults.

84 An updated systematic literature search reviewed seven databases [Pubmed, Medline, Embase, CINAHL,  
85 Web of Science, Scopus (Web of Science), Epistemonikos, and Cochrane library] for relevant data  
86 published during April 2019 to February 2021. All relevant studies from the previous search by NIPH  
87 (published during January 2016 to March 2019) were also included in our review. Authors were  
88 contacted for additional information whenever possible. The results of all searches were entered into  
89 the Covidence systematic review software program [18].

90 The protocol for this review was developed in line with PRISMA-P recommendations [19] and registered  
91 with PROSPERO (CRD42021258668). The protocol was amended in February 2022 to include an  
92 additional year of search that was performed after the initial review. This search was conducted on April  
93 4, 2022, to identify additional titles published during February 13, 2021, to March 15, 2022, to update  
94 the review.

#### 95 *Inclusion and exclusion criteria*

96 Data on PCV13 and PPSV23 efficacy or effectiveness against VT-IPD (defined as detection of *S.*  
97 *pneumoniae* in normally sterile sites, such as bacteremia and meningitis that are caused by serotypes  
98 contained in the vaccines) and VT-pneumococcal pneumonia (defined as pneumonia due to a *S.*  
99 *pneumoniae* serotype contained in the vaccines) were included.

100 We included published RCTs and observational studies (prospective and retrospective comparative  
101 cohort studies, case-control or nested case-control studies, indirect cohort studies, screening method  
102 studies) from middle- and high-income settings that evaluated direct effects of pneumococcal  
103 vaccination on adults ( $\geq 16$  years). Systematic reviews on PCV13 or PPSV23 efficacy or effectiveness were  
104 included to leverage their bibliographies for relevant data. Only English language studies were included.

105 We excluded studies assessing vaccine impact, case reports, case-series, animal studies, modelling  
106 studies, health economic evaluations, pneumococcal carriage studies, narrative reviews, studies that  
107 only included data on vaccines that are not currently used in the United States (e.g., PCV7, PCV10), ,  
108 studies evaluating indirect effects of pediatric pneumococcal vaccination on adult populations, and  
109 studies specifically targeting adults with immunocompromising conditions. In addition, because  
110 pneumococcal disease epidemiology differs from that in the United States, we excluded studies  
111 conducted in low-income settings.

#### 112 *Data abstraction and cleaning*

113 Titles and abstracts of all citations identified through the literature search were independently screened  
114 for relevance and inclusion by two reviewers using Covidence [20]. Articles meeting inclusion through  
115 title and abstract screening were then double screened through full-text review. Discordant reviews  
116 during title and abstract or full-text review were blindly reviewed for inclusion by an independent third  
117 reviewer.

118 Data were independently abstracted by two reviewers for study information (study characteristics,  
119 methods, results) using standardized data collection tools and entered into a Microsoft Excel  
120 spreadsheet.

121 Data were also assessed for quality of evidence. Randomized studies were assessed for quality using the  
122 Cochrane Risk of Bias 2.0 tool [21], which included consideration of the appropriate generation of  
123 random allocation sequences; concealment of the allocation sequences; blinding of participants,  
124 healthcare providers, data collectors, and outcome adjudicators; and proportion of patients lost to  
125 follow-up. Non-randomized studies were assessed considering the data elements included in the  
126 Newcastle-Ottawa scale (NOS) [22] to address potential sources of bias in cohort and case-control  
127 studies. Each study was assessed for risk of bias independently by two reviewers. A third reviewer was  
128 consulted when there was discordance of overall quality of evidence between the two independent  
129 reviewers. Studies with scores  $\geq 7$  (out of 9) were deemed high quality/low risk of bias, scores between 4  
130 to 6 (out of 9) were deemed medium quality/some risk of bias, and scores  $\leq 3$  were deemed low  
131 quality/high risk of bias.

### 132 *Data analysis*

133 We conducted descriptive analyses of studies stratified by outcome (VT-IPD or VT- pneumococcal  
134 pneumonia), vaccine product (PCV13 or PPSV23), and study design (RCT or observational study). When  
135 feasible, we conducted meta-analyses by outcome, product, and study design using Comprehensive  
136 Meta-Analysis Version 3 [23]. Random effects models were used to pool estimates by stratum. Because  
137 PPSV23 has been used for adults much longer than PCV13, time since PPSV23 vaccination was more  
138 variable across studies compared with PCV13 studies. To account for waning of vaccine effectiveness  
139 over time [24-29], we limited the PPSV23 analysis to data from individuals who were vaccinated within 5  
140 years of assessment. When data were available, we performed sub-analyses by underlying conditions  
141 and limiting to a younger age group of adults aged 65 through 74 years to account for heterogeneity in  
142 the study population between observational studies.

### 143 **Results**

144 *Literature Search*

145 The literature search yielded a total of 5,085 articles, 2,499 from the NIPH search that covered titles  
146 published during January 2016 to April 2019 and 2,586 from the updated search that covers titles  
147 published during April 2019 to March 2022. From the updated search, 1,764 studies were screened for  
148 eligibility; 1,525 were excluded during title and abstract screening. During the full-text review, 239  
149 articles were screened for eligibility; 229 were excluded. Ten studies were included from the updated  
150 searches and nine studies were included from the NIPH search, totaling 19 studies for inclusion in the  
151 analysis (Figure 1). Seven studies evaluated PCV13 and 13 evaluated PPSV23; one study evaluated both  
152 PCV13 and PPSV23 against VT-pneumococcal pneumonia [30]. Efficacy or effectiveness against VT-IPD  
153 was evaluated in 13 studies and against VT-pneumococcal pneumonia in eight studies; two studies  
154 evaluated pneumococcal vaccine effectiveness against both VT-IPD and VT-pneumococcal pneumonia  
155 (Table) [5, 31].

156 **Figure 1. PRISMA Study flow diagram**

157



158 **Table. Characteristics of Included Pneumococcal Vaccine Effectiveness Studies**

Author and publication year	Country	Population	Study Design	Study Period	Outcome	VE (95% CI)**	Study Quality
<b>PCV13</b>							
Bonten 2015*	Netherlands	Dutch pneumococcal vaccine-naïve, community-dwelling adults ≥65 years	Randomized Controlled Trial (CAPITA)	2008 – 2013	VT- IPD	75% (41, 91)	High***
					Non-invasive non-bacteremic VT-CAP	45% (14, 65)	
Heo 2022	South Korea	Hospitalized adults ≥65 years	Test-negative	2015 - 2017	PCV-13-type community-acquired pneumonia	41% (-104, 83)	High
Lewis 2019*	US	Kaiser Permanente Northern California members with no record of prior receipt of PPSV23, adults ≥65 years	Cohort study	2014 – 2018	VT- IPD	68% (38, 84)	High

McLaughlin 2018*	US	Inpatient adults ≥65 years	Test-negative	2013 – 2016	Non-bacteremic VT-pneumococcal pneumonia	68% (-6, 90)	High
Pilishvili 2018	US	Active Bacterial Core Surveillance (ABCs) IPD cases, adults ≥65 years	Case-control; controls identified using ReferenceUSAGov	2015 - 2017	PCV13-type + 6C IPD	59% (11, 81)	High
Pilishvili 2018	US	Active Bacterial Core Surveillance (ABCs) IPD cases, adults ≥65 years	Case-control; controls identified as Medicare beneficiaries with no record of IPD or pneumonia	2015 – 2016	PCV13-type + 6C IPD	47% (4, 71)	High
Prato 2018	Italy	Inpatient and outpatient adults ≥65 years	Test-negative	2013 - 2015	VT-pneumococcal pneumonia	38% (-132, 89)	Low
<b>PPSV23</b>							
Andrews 2012	UK	Adults ≥65 years	Indirect cohort	2003 - 2010	VT-IPD	48% (32, 60)	Medium

Chandler 2022	US	Inpatient adults	Test-negative	2014 - 2017	VT-pneumococcal pneumonia	2% (-52, 37)	High
Djennad 2018	UK	Adults ≥65 years	Indirect cohort	2012 - 2016	VT-IPD	41% (23, 54)	High
Dominguez 2005	Spain	Adults ≥65 years	Case-control; hospital controls	2001 - 2002	VT-IPD	64% (31, 82)	Medium
Gutiérrez - Rodriguez 2014	Spain	Adults ≥60 years	Indirect cohort	2008 - 2011	VT-IPD	44% (19, 62)	High
Heo 2022	South Korea	Hospitalized adults ≥65 years	Test-negative	2015 - 2017	VT-pneumococcal pneumonia	6% (-74, 50)	High
Kim 2019	South Korea	Adults ≥65 years	Case-control	2013 - 2015	VT-IPD	42% (-2, 67)	High
					VT- non bacteremic pneumococcal pneumonia	-2% (-40, 26)	
Lawrence 2020	England	Adults ≥16 years	Case-control	2013 – 2018	VT- pneumococcal pneumonia	46% (5, 69)	Medium

					(PPSV23 non-PCV13 serotypes)		
Perniciaro 2021	Germany	Adults ≥60 years (German National Reference Center for Streptococci (GNRCS))	Indirect cohort	2018 – 2019	VT-IPD (PPSV23 non-PCV13 serotypes)	35% (-14, 65)	High
Rudnick 2013	Canada	Adults ≥65 years	Indirect cohort	1995 - 2011	VT-IPD	41% (21, 56)	Medium
Shimbashi 2020	Japan	Adults ≥20 years	Indirect cohort	2013 - 2017	VT-IPD	39.3% (-2.9, 64.2)	Medium
		Adults ≥65 years				39.4% (-6.1, 65.3)	
Su 2021	Taiwan	Adults ≥75 years	Indirect cohort	2008 – 2016	VT-IPD	74% (39, 89)	High
			Screening method			43.4% (34.4, 51.2)	
Suzuki 2017	Japan	Adults ≥65 years	Test- negative	2011 - 2014	VT- pneumococcal pneumonia	34% (6, 53)	High

159 \*Study funded by industry

160 \*\* VE estimate presented as reported in study for overall estimate, all age groups, shortest time since vaccination (if stratified estimates

161 provided)

162 \*\*\* Cochrane Risk of Bias tool used to assess quality of evidence

163 VE= vaccine effectiveness; IPD=invasive pneumococcal disease; CAP= community-acquired pneumonia

164 *Vaccine-type invasive pneumococcal disease*

165 PCV13

166 We identified four studies evaluating PCV13 efficacy or effectiveness against VT-IPD. Only one RCT was  
167 identified, with a reported efficacy of 75% (95% CI: 41%, 91%) against VT-IPD in Dutch pneumococcal  
168 vaccine-naïve, community-dwelling adults aged  $\geq 65$  years [5]. Vaccine effectiveness (VE) estimates from  
169 three observational studies ranged from 47%–68% against VT-IPD in adults aged  $\geq 65$  years [32-34]  
170 (Table 1). Lewis et al evaluated PCV13 VE in a cohort of U.S. adults aged  $\geq 65$  years who were enrolled in  
171 Kaiser Permanente Northern California insurance and had not received PPSV23 before age 65 years.  
172 PCV13 VE was 68% (95% CI: 38%, 84%) against all VT-IPD, and 53% (95% CI: -10%, 80%) against serotype  
173 3 IPD; the study reported an increase in the incidence of IPD during the study period (2014–2018),  
174 largely due to serotype 3. The other two observational studies by Pilishvili et al were case-control  
175 studies that used Active Bacterial Core surveillance data to identify cases, but different sources to  
176 identify controls [33, 34]. The VE estimate for PCV13 against IPD caused by PCV13 + 6C serotypes was  
177 59% (95% CI: 11%, 81%) using controls identified from the commercial database ReferenceUSAGov  
178 (InfoGroup) [33] and 47% (95% CI: 4%, 71%) using Medicare beneficiaries as controls; this estimate  
179 increased to 67% (95% CI: 11%, 88%) when excluding serotype 3 IPD cases [34]. Due to overlap in cases  
180 between the two Pilishvili et al studies, a pooled VE was not estimated between studies.

181 PPSV23

182 We did not identify any RCTs assessing PPSV23 efficacy against VT-IPD. Nine observational studies  
183 reported VE among those who received PPSV23 within 5 years of the study assessment [24-26, 28, 31,  
184 35-38]. Of these, seven were indirect cohorts and two were case-control studies. Studies evaluated VE  
185 among adults aged  $\geq 60$  years from Canada, Germany, United Kingdom (n=2), South Korea, Japan,  
186 Taiwan, and Spain (n=2). Of note, Perniciaro et al reported a -30% (95% CI: -159%, 31%) PPSV23  
187 effectiveness against VT-IPD; however, the authors observed that vaccination rates were low (16%)

188 among adults who had received PPSV23 within five years prior to the study. Additionally, over 20% of  
189 cases were caused by serotype 3. Therefore, we report the VE against PPSV23/non-PCV13 serotype IPD,  
190 which was 35% (95% CI: -14%, 65%) [38]. The pooled VE estimate from these nine observational studies  
191 was 45% (95% CI: 37%, 51%;  $I^2=0\%$ ) (Figure 2). When limited to three studies in adults without  
192 immunocompromising conditions [24, 25, 28], the pooled VE estimate was 60% (95% CI: 47%, 69%;  $I^2=$   
193 0%) (Figure 3). The pooled VE estimate for a sub-analysis restricting to adults aged 65 through 74 years  
194 [24, 25, 31] was 52% (95% CI: 36%, 64%;  $I^2= 5.2\%$ ) (Figure 4).

195 **Figure 2. Pooled Vaccine Effectiveness Estimate of 23-Valent Pneumococcal Polysaccharide Vaccine**  
196 **Against Vaccine-Type Invasive Pneumococcal Disease in Adults Aged  $\geq 60$  Years: Observational**  
197 **studies, <5 years since vaccination**

198 **Figure 3. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against**  
199 **Vaccine-Type Invasive Pneumococcal Disease in Healthy Adults: Observational studies, <5 years since**  
200 **vaccination**

201 **Figure 4. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against**  
202 **Vaccine-Type Invasive Pneumococcal Disease in Adults Aged 65–74 years: Observational studies, <5**  
203 **years since vaccination**

204 *Vaccine-type Pneumococcal Pneumonia*

205 PCV13

206 We identified four studies evaluating PCV13 efficacy or effectiveness against VT-pneumococcal  
207 pneumonia. One RCT, among Dutch adults aged  $\geq 65$  years, reported an efficacy of 45% (95% CI: 14%,  
208 65%) against the first episode of VT-nonbacteremic and noninvasive pneumococcal pneumonia [5]. In  
209 addition to the RCT, we identified three test-negative design (TND) observational studies for PCV13. The  
210 study by Prato et al was conducted among outpatient and inpatient Italian adults aged  $\geq 65$  years living  
211 in the Apulia region [39]. Many participants had one or more underlying comorbidity including chronic  
212 heart disease (53%), chronic respiratory disease (44%), and diabetes (25%). Patients were considered to  
213 have pneumococcal pneumonia if they had a positive PCR result for *S. pneumoniae* from blood, sputum,

214 or bronchoalveolar-lavage. Prato et al reported a crude VE of 38% (95% CI: -132%, 89%) against VT-  
215 pneumococcal pneumonia, and an adjusted VE was not reported [39]. The study by McLaughlin et al was  
216 conducted as a nested study within a larger population-based surveillance study of U.S. adults in  
217 Kentucky. Adults aged  $\geq 65$  years hospitalized with community acquired pneumonia (CAP) were  
218 considered for enrollment. Most participants (88%) had one or more at-risk (defined as  
219 immunocompetent, but presence of a chronic disease such as congestive heart failure, diabetes  
220 mellitus, or liver disease) or high-risk (defined as immunocompromised) condition, and almost half of  
221 participants were considered high-risk (46%). The adjusted VE was 68% (95% CI: -6%, 90%) against  
222 nonbacteremic VT-pneumococcal pneumonia [40]. Heo et al evaluated the effectiveness of PCV13,  
223 PPSV23, and sequential PCV13/PPSV23 vaccination against pneumococcal pneumonia among older  
224 South Korean adults aged  $\geq 65$  years hospitalized with CAP. The mean age of participants was  $76.7 \pm 6.9$   
225 years and many participants had  $\geq 1$  underlying comorbidity (80%) or  $\geq 2$  underlying comorbidities (45%).  
226 The adjusted VE against VT-pneumococcal pneumonia was 41% (95% CI: -104%, 83%) for all adults aged  
227  $\geq 65$  years, [30]. Pooled VE of the TND observational studies was not estimated since Prato et al only  
228 reported a crude VE estimate.

229 PPSV23

230 We did not identify any RCTs evaluating efficacy of PPSV23 against VT-pneumococcal pneumonia. We  
231 identified five observational studies with VE estimates ranging from -2% to 46% [29-31, 41, 42]. The  
232 study by Kim et al was a hospital-based case-control study conducted among South Korean adults aged  
233  $\geq 65$  years. The median age of the study population was 76 years and many participants had one or more  
234 underlying medical conditions such as chronic pulmonary disease (37% of cases, 23% of controls) or  
235 diabetes mellitus (24% of cases, 30% of controls). Approximately 26% of cases and 37% of controls had  
236 an immunocompromising condition. The adjusted VE against VT-nonbacteremic pneumococcal



237 pneumonia was -2% (95% CI: -40%, 26%) [31]. The four remaining observational studies were TND.  
238 Lawrence et al used a nested TND of a prospective cohort study of adults aged  $\geq 16$  years hospitalized  
239 with CAP at two hospitals in England. The mean age was similar between cases and controls (66.5 versus  
240 65.4 years). The most common comorbidities among cases and controls were chronic obstructive  
241 pulmonary disease (COPD) (24% for cases and controls), chronic lung disease (27% for cases and  
242 controls), and hypertension (24% of cases, 25% of controls). The adjusted VE of PPSV23 against VT-  
243 pneumococcal pneumonia (non-bacteremic and bacteremic) among those vaccinated  $< 5$  years was -7%  
244 (95% CI: -54%, 26%). Lawrence et al observed that serotype 5 caused the largest proportion of cases of  
245 PPSV23 serotype pneumonia  $< 5$  years since vaccination and considered the potential cross-reactivity  
246 with other streptococcal strains that express serotype 5; however, the authors noted the potential  
247 cross-reactivity did not alone explain the difference in effects among vaccinated and unvaccinated  
248 patients. Therefore, we report the VE against PPSV23/non-PCV13 serotypes pneumococcal pneumonia,  
249 which was 46% (95% CI: 5%, 69%) [41]. Suzuki et al conducted a prospective TND study among adults  
250 aged  $\geq 65$  years at four community-based hospitals in Japan. Presence of underlying medical conditions  
251 was similar between cases and controls. The adjusted VE of PPSV23 against VT-pneumococcal  
252 pneumonia among outpatients and inpatients was 34% (95% CI: 6%, 53%) [29]. Heo et al, described  
253 above, reported an adjusted VE of 6% (95% CI: -74%, 50%) against VT-pneumococcal pneumonia among  
254 participants aged  $\geq 65$  years [30]. Chandler et al conducted a TND study among hospitalized CAP patients  
255 identified through the University of Louisville Pneumonia Study database that was also used for the  
256 study by McLaughlin et al [40]. The median age of vaccinated patients was 68 years, compared to 65  
257 years among non-vaccinated patients. Vaccinated patients were more likely to have comorbid  
258 conditions such as COPD (58% among vaccinated patients versus 47% among unvaccinated patients),  
259 renal failure (33% versus 26%), or diabetes (37% versus 31%). Chandler et al reported 2% (95% CI: -52%,  
260 37%) vaccine effectiveness against VT-pneumococcal pneumonia in adults aged  $\geq 65$  years who received

261 PPSV23 within 5 years of assessment. [42]. Pooled VE of PPSV23 against VT-pneumococcal pneumonia  
262 from the five observational studies was 18% (95% CI: -4%, 35%;  $I^2=0\%$ ) (Figure 5). When limited to adults  
263 aged 65 through 74 years, the pooled VE estimate from three studies [29-31] was 26% (95% CI: -6%,  
264 49%;  $I^2=0\%$ ) (Figure 6).

265 **Figure 5. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against**  
266 **Vaccine-Type Pneumococcal Pneumonia in Adults aged  $\geq 16$  Years: Observational studies, <5 years**  
267 **since vaccination**

268 **Figure 6. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against**  
269 **Vaccine-Type Pneumococcal Pneumonia in Adults Aged 65 – 74 Years: Observational studies, <5 years**  
270 **since vaccination**

#### 271 *Quality of Evidence*

272 The risk of bias for the one RCT [5] was low; therefore, the quality of evidence was high for this study.  
273 Regarding observational studies, scores using the Newcastle-Ottawa scale ranged from 3 to 8 (out of 9)  
274 for PCV13 studies; three studies were deemed high quality (score of 7 or 8). Prato et al scored 3 for lack  
275 of information regarding selection of controls and exposure criteria as well as lack of controlling for  
276 potential confounders; it was rated low for quality of evidence. For PPSV23 observational studies, eight  
277 studies were deemed high quality (score of 7 to 8) [25, 26, 29-31, 37, 38, 42] and five were deemed  
278 medium quality (score of 4 to 6) [24, 28, 35, 36, 41]. All studies that scored medium quality lacked  
279 information regarding source of controls or ascertainment of exposure (i.e., how vaccination history was  
280 obtained).

#### 281 **Discussion**

282 Recent data continue to support that both PCV13 and PPSV23 are effective against VT-IPD in adults.  
283 However, there are a few differences in the published studies that warrant additional discussion. When  
284 considering PCV13, the VE estimates from Pilishvili et al were lower than the estimates from the RCT;  
285 this is expected, as effectiveness estimates from observational studies are often lower than efficacy

286 estimates from clinical trials, which occur in a more controlled setting. Furthermore, the lower observed  
287 estimates could be due to differences in the study population. Specifically, 54–60% of cases and 31–32%  
288 of controls in the case-control studies by Pilishvili et al had immunocompromising conditions, whereas  
289 adults with immunocompromising conditions at enrollment were not included in the RCT. Regarding  
290 PCV13 effectiveness against VT-pneumococcal pneumonia, findings from observational studies  
291 supported findings from the RCT, which showed 45% effectiveness. However, estimates from the  
292 observational studies had wide confidence intervals.

293 When considering PPSV23, the pooled VE estimate for PPSV23 against VT-IPD was slightly lower than  
294 what was observed for PCV13, even after limiting the data to <5 years since vaccination. These findings  
295 are not unexpected as immunogenicity studies have observed polysaccharide vaccines to be less  
296 immunogenic compared to conjugate vaccines. This review reinforced the existing evidence for PPSV23  
297 effectiveness against VT-IPD.

298 Until recently, there were limited data specifically assessing PPSV23 VE against VT-pneumococcal  
299 pneumonia. Previous studies that reported PPSV23 effectiveness against pneumococcal pneumonia or  
300 CAP had variable results [43-45]. A review and meta-analysis by Falkenhorst et al estimated a pooled VE  
301 against pneumococcal pneumonia of 64% (95%CI: 35– 80%) in clinical trials and 48% (95%CI: 25–63%) in  
302 cohort studies, after excluding studies with high risk of bias [43]. Conversely, a review by Schiffner-Rohe  
303 et al reported that three of four studies showed no efficacy against pneumococcal pneumonia [44].  
304 Recent studies assessing PPSV23 effectiveness against VT-pneumococcal pneumonia allowed us to  
305 conduct a pooled VE estimate, which suggests that PPSV23 provides some protection against VT-  
306 pneumonia within 5 years of vaccination.

307 In October 2021, based in part on this analysis, the U.S. ACIP voted to recommend PCV15 in series with  
308 PPSV23 or PCV20 use in U.S. adults who have not previously received a PCV [9]. This recommendation

309 simplified previous recommendations on pneumococcal vaccine use in adults, which differed by age-  
310 and risk-groups [6]. The new recommendations also provide an opportunity for broader PCV coverage  
311 among adults compared to previous recommendations, in which routine PCV use was only  
312 recommended for adults with immunocompromising conditions. Because licensure of PCV15 and PCV20  
313 was based on immunogenicity and safety data only, there are remaining questions regarding clinical  
314 implications of implementing these vaccines. For example, in clinical trials, PCV20 elicited slightly lower  
315 immune responses compared with PCV13 for the 13 shared serotypes, although noninferiority criteria  
316 were met [13]. The clinical implications of these findings, especially in adults with immunocompromising  
317 conditions who were not included in Phase II and III trials, are unknown. Furthermore, it is unknown  
318 whether PCV15 use in series with PPSV23 will provide better protection against the 15 shared serotypes  
319 compared to PCV20 only. A study from Korea reported that among adults aged 65 through 74 years,  
320 PCV13 in series with PPSV23 might result in improved protection against non-bacteremic VT-  
321 pneumococcal pneumonia compared with PCV13 or PPSV23 alone [30].

322 There are limitations to our review. We identified only one RCT that evaluated PCV13 [5] and none that  
323 evaluated PPSV23 efficacy against VT-pneumococcal disease in adults. RCTs provide the most rigorous  
324 evidence of vaccine efficacy. However, we identified several observational studies evaluating both  
325 PCV13 and PPSV23 effectiveness against VT-IPD and VT-pneumonia. Heterogeneity in study populations,  
326 e.g., different age distributions and different proportions of people with underlying conditions included,  
327 for PCV13 and PPSV23 studies may have affected the VE estimates. Furthermore, these differences in  
328 populations may in part contribute to the range of results observed across studies, though we have  
329 attempted to address this limitation by conducting stratified analysis of the data. Despite these  
330 limitations, this was an exhaustive and systematic review of literature on pneumococcal vaccine  
331 products for adult use and provides a comprehensive, current landscape of the evidence regarding VE  
332 for PCV13 and PPSV23 against VT-IPD and VT- pneumococcal pneumonia in adults.

333 In conclusion, our review showed that PCV13 and PPSV23 are both effective against VT-IPD and VT-  
334 pneumococcal pneumonia in adults. These data helped inform decisions on PCV15 and PCV20 use in  
335 adults in the United States, which currently do not have efficacy or effectiveness data against clinical  
336 outcomes and could be used to inform similar decision in other countries. Post-licensure effectiveness  
337 and impact studies of PCV15 and PCV20 on pneumococcal disease in adults are needed to assess the  
338 impact of the new recommendations.

339

## 340 References

- 341 1. Gierke R, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison L, et al. 1299. Epidemiology  
342 of Invasive Pneumococcal Disease (IPD) in the United States 2011-2019. Open Forum Infectious  
343 Diseases. 2021;8(Supplement\_1):S737-S8.
- 344 2. Isturiz R, Grant L, Gray S, Alexander-Parrish R, Jiang Q, Jodar L, et al. Expanded Analysis of 20  
345 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia  
346 in Hospitalized US Adults. Clin Infect Dis. 2021;73(7):1216-22.
- 347 3. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide  
348 vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee  
349 on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-9.
- 350 4. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent  
351 pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults  
352 aged  $\geq 65$  years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR  
353 Morb Mortal Wkly Rep. 2014;63(37):822-5.
- 354 5. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide  
355 conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25.
- 356 6. Matanock A, Lee G, Gierke R, Kobayashi M, Leidner A, Pilishvili T. Use of 13-Valent  
357 Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults  
358 Aged  $\geq 65$  Years: Updated Recommendations of the Advisory Committee on Immunization Practices.  
359 MMWR Morb Mortal Wkly Rep. 2019;68(46):1069-75.
- 360 7. Food and Drug Administration. VAXNEUVANCE 2021 [Available from:  
361 <https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance>.
- 362 8. Food and Drug Administration. PREVNAR 20 2021 [Available from:  
363 <https://www.fda.gov/vaccines-blood-biologics/vaccines/prevnar-20>.

- 364 9. Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-Valent  
365 Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults:  
366 Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.  
367 MMWR Morb Mortal Wkly Rep. 2022;71(4):109-17.
- 368 10. Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, et al. Safety and  
369 immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults  
370 ≥50 years of age. *Vaccine*. 2018;36(45):6875-82.
- 371 11. Peterson JT, Stacey HL, MacNair JE, Li J, Hartzel JS, Sterling TM, et al. Safety and immunogenicity  
372 of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine  
373 in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.  
374 *Human Vaccines and Immunotherapeutics*. 2019;15(3):540-8.
- 375 12. Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, et al. A phase 3 trial of  
376 safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared  
377 with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).  
378 *Vaccine*. 2022;40(1):162-72.
- 379 13. Essink B, Sabharwal C, Cannon K, Frenck R, Lal H, Xu X, et al. Pivotal Phase 3 Randomized Clinical  
380 Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in  
381 Adults 18 Years and Older. *Clin Infect Dis*. 2021.
- 382 14. Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, et al. Safety, Tolerability, and  
383 Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of  
384 Age. *Clin Infect Dis*. 2020.
- 385 15. Hammitt LL, Quinn D, Janczewska E, Pasquel FJ, Tytus R, Rajender Reddy K, et al.  
386 Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in

- 387 Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A  
388 Randomized Phase 3 Trial (PNEU-DAY). *Open Forum Infect Dis.* 2022;9(3):ofab605.
- 389 16. Mohapi L, Pinedo Y, Osiyemi O, Supparatpinyo K, Ratanasuwan W, Molina JM, et al. Safety and  
390 immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. *Aids.*  
391 2022;36(3):373-82.
- 392 17. Berild JD, Winje BA, Vestrheim DF, Slotved HC, Valentiner-Branth P, Roth A, et al. A Systematic  
393 Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal  
394 Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population. *Pathogens.*  
395 2020;9(4).
- 396 18. Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia 2021.
- 397 19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA  
398 statement for reporting systematic reviews and meta-analyses of studies that evaluate health care  
399 interventions: explanation and elaboration. *PLoS Med.* 2009;6(7):e1000100.
- 400 20. Innovation VH. Covidence Systematic Review software.
- 401 21. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane  
402 Collaboration's tool for assessing risk of bias in randomised trials. *Bmj.* 2011;343:d5928.
- 403 22. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale  
404 (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. . 2000; .
- 405 23. Borenstein M, Hedges L, Higgins J, & Rothstein, H. *Comprehensive Meta-Analysis Version 3.*  
406 Englewood, NJ Biostat; 2013.
- 407 24. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent  
408 pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England  
409 and Wales. *Vaccine.* 2012;30(48):6802-8.



- 410 25. Djennad A, Ramsay ME, Pebody R, Fry NK, Sheppard C, Ladhani SN, et al. Effectiveness of 23-  
411 Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence  
412 from 2000 to 2017 in Those Aged 65 and Over in England and Wales. *EClinicalMedicine*. 2018;6:42-50.
- 413 26. Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, Sanz Moreno JC, Cordoba  
414 Deorador E, Lasheras Carbajo MD, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine  
415 in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011. *Euro Surveill*.  
416 2014;19(40):20922.
- 417 27. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E,  
418 Raga-Luria X, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against  
419 community-acquired pneumonia in the general population aged  $\geq$  60 years: 3 years of follow-up in the  
420 CAPAMIS study. *Clin Infect Dis*. 2014;58(7):909-17.
- 421 28. Rudnick W, Liu Z, Shigayeva A, Low DE, Green K, Plevneshi A, et al. Pneumococcal vaccination  
422 programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995-2011. *Vaccine*.  
423 2013;31(49):5863-71.
- 424 29. Suzuki M, Dhoubhadel BG, Ishifuji T, Yasunami M, Yaegashi M, Asoh N, et al. Serotype-specific  
425 effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in  
426 adults aged 65 years or older: a multicentre, prospective, test-negative design study. *Lancet Infect Dis*.  
427 2017;17(3):313-21.
- 428 30. Heo JY, Seo YB, Choi WS, Kim EJ, Jeong HW, Lee J, et al. Effectiveness of Pneumococcal  
429 Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-  
430 Negative Study. *J Infect Dis*. 2022;225(5):836-45.
- 431 31. Kim JH, Chun BC, Song JY, Kim HY, Bae IG, Kim DM, et al. Direct effectiveness of pneumococcal  
432 polysaccharide vaccine against invasive pneumococcal disease and non-bacteremic pneumococcal

- 433 pneumonia in elderly population in the era of pneumococcal conjugate vaccine: A case-control study.  
434 *Vaccine*. 2019;37(21):2797-804.
- 435 32. Lewis N, Hsiao A, Hansen J, Yee A, Chao C, Suaya JA, et al. Effectiveness of 13-valent  
436 pneumococcal conjugate vaccine against invasive pneumococcal disease in older adults. *Open Forum*  
437 *Infectious Diseases*. 2019;6 (Supplement 2):S953-S4.
- 438 33. Pilishvili T, Almendares O, Xing W, Farley MM, Schaffner W, Thomas A, et al. Effectiveness of  
439 Pneumococcal Vaccines against Invasive Pneumococcal Disease (IPD) among Adults  $\geq$ 65 Years Old in  
440 the United States. Melbourne, Australia 2018.
- 441 34. Pilishvili T, Almendares OM, Nanduri S, Warnock R, Wu X, McKean S, et al. Evaluation of  
442 pneumococcal vaccine effectiveness against invasive pneumococcal disease among us medicare  
443 beneficiaries  $\geq$ 65 years old. *Open Forum Infectious Diseases*. 2018;5 (Supplement 1):S10-S1.
- 444 35. Dominguez A, Salleras L, Fedson DS, Izquierdo C, Ruiz L, Ciruela P. Effectiveness of Pneumococcal  
445 Vaccination for Elderly People in Catalonia, Spain: A Case-control Study. *Clin Inf Dis*. 2005;40:1250-57.
- 446 36. Shimbashi R, Suzuki M, Chang B, Watanabe H, Tanabe Y, Kuronuma K, et al. Effectiveness of 23-  
447 valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan,  
448 2013-2017. *Emerging Infectious Diseases*. 2020;26(10):2378-86.
- 449 37. Su WJ, Chuang PH, Chang LY, Lo HY, Chiang CS, Wang ET, et al. Application of the screening and  
450 indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75  
451 years and older in Taiwan. *BMC Infectious Diseases*. 2021;21(1):45.
- 452 38. Perniciaro S, van der Linden M. Pneumococcal vaccine uptake and vaccine effectiveness in older  
453 adults with invasive pneumococcal disease in Germany: A retrospective cohort study. *The Lancet*  
454 *Regional Health - Europe*. 2021;7:100126.

- 455 39. Prato R, Fortunato F, Cappelli MG, Chironna M, Martinelli D. Effectiveness of the 13-valent  
456 pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year  
457 prospective cohort. *BMJ Open*. 2018;8(3):e019034.
- 458 40. McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, et al. Effectiveness of 13-  
459 Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in  
460 Older US Adults: A Test-Negative Design. *Clinical Infectious Diseases*. 2018;67(10):1498-506.
- 461 41. Lawrence H, Pick H, Baskaran V, Daniel P, Rodrigo C, Ashton D, et al. Effectiveness of the 23-  
462 valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in  
463 adults: A case-control test-negative design study. *PLoS Medicine / Public Library of Science*.  
464 2020;17(10):e1003326.
- 465 42. Chandler T, Furmanek S, Carrico R, Balcom D, Arnold F, Ramirez J. 23-Valent Pneumococcal  
466 Polysaccharide Vaccination Does Not Prevent Community-Acquired Pneumonia Hospitalizations Due to  
467 Vaccine-Type *Streptococcus pneumoniae*. *Microorganisms*. 2022;10(3).
- 468 43. Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E, Wichmann O, Bogdan C.  
469 Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal  
470 Disease in the Elderly: Systematic Review and Meta-Analysis. *PLOS ONE*. 2017;12(1):e0169368.
- 471 44. Schiffner-Rohe J, Witt A, Hemmerling J, von Eiff C, Leverkus F-W. Efficacy of PPV23 in Preventing  
472 Pneumococcal Pneumonia in Adults at Increased Risk – A Systematic Review and Meta-Analysis. *PLOS*  
473 *ONE*. 2016;11(1):e0146338.
- 474 45. Tin Tin Htar M, Stuurman AL, Ferreira G, Alicino C, Bollaerts K, Paganino C, et al. Effectiveness of  
475 pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of  
476 observational studies. *PLoS One*. 2017;12(5):e0177985.

477

## Appendix 1. Systematic literature search strategy

Database	Strategy
<p><b>Medline</b></p> <p><b>(OVID)</b></p>	<ol style="list-style-type: none"> <li>1. streptococcus pneumoniae/</li> <li>2. (pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae").tw,kf.</li> <li>3. 1 or 2</li> <li>4. vaccination/ or immunization/ or Vaccines, Conjugate/</li> <li>5. (vaccine? or vaccination? or immunisation or immunization).tw,kf.</li> <li>6. 4 or 5</li> <li>7. Pneumococcal Vaccines/</li> <li>8. (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or "23valent").tw,kf.</li> <li>9. 7 or 8</li> <li>10. (3 and 6)</li> <li>11. 10 or 9</li> <li>12. comparative effectiveness research/ or treatment outcome/ or Vaccine Potency/</li> <li>13. (efficacy or effectiveness or effects or "immune response" or impact or "treatment outcome").tw,kf.</li> <li>14. 12 or 13</li> <li>15. adult/ or aged/ or "aged, 80 and over"/ or frail elderly/</li> </ol>

	<p>16. (adult? or elderly or elderlies).tw,kf.</p> <p>17. 15 or 16</p> <p>18. 11 and 14 and 17</p> <p>19. (201904* OR 201905* OR 201906* OR 201907* OR 201908* OR 201909* OR 201910* OR 201911* OR 201912* OR 2020* OR 2021*).ed,ep,yr,dp,dt.</p> <p>20. 17 and 18</p>
<p><b>Embase</b></p> <p><b>(OVID)</b></p> <p><b>1988-</b></p>	<p>1. Streptococcus pneumoniae/</p> <p>2. (pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae").tw,kw.</p> <p>3. 1 or 2</p> <p>4. vaccination/ or immunization/ or vaccine/</p> <p>5. (vaccine? or vaccination? or immunisation or immunization).tw,kw.</p> <p>6. 4 or 5</p> <p>7. Pneumococcus vaccine/</p> <p>8. (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or "23valent").tw,kw.</p> <p>9. 7 or 8</p> <p>10. 3 and 6</p>

	<p>11. 9 OR 10</p> <p>12. comparative effectiveness/ or treatment outcome/</p> <p>13. (efficacy or effectiveness or effects or "immune response" or impact or "treatment outcome").tw,kw.</p> <p>14. 12 or 13</p> <p>15. aged/ or adult/ or aged hospital patient/ or frail elderly/ or institutionalized elderly/ or very elderly/</p> <p>16. (adult? or elderly or elderlies).tw,kw.</p> <p>17. 15 or 16</p> <p>18. 11 and 14 and 17</p> <p>19. (201904* OR 201905* OR 201906* OR 201907* OR 201908* OR 201909* OR 201910* OR 201911* OR 201912* OR 2020* OR 2021*).dc</p> <p>20. limit 19 to (conference abstracts or embase)</p>
<p><b>Cochrane Library</b></p>	<p>(</p> <p>(</p> <p>(pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae"):ti,ab</p> <p>AND</p> <p>([mh Vaccines] OR [mh Immunization] OR (vaccine# or vaccination# or immunisation or immunization):ti,ab)</p> <p>)</p>


	<p>OR</p> <p>(MH "Pneumococcal Vaccine") OR TI (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or "23valent") OR AB (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or "23valent")</p> <p>)</p> <p>AND</p> <p>[mh "Treatment Outcomes"] OR (efficacy or effectiveness or effects or "immune response" or impact or "treatment outcome"):ti,ab</p> <p>AND</p> <p>[mh Adult] OR [mh Aged+] OR (adult# or elderly or elderlies):ti,ab</p>
<p><b>CINAHL</b></p> <p><b>(EbscoHost)</b></p>	<p>(</p> <p>(TI (pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae") OR AB (pneumococcal or pneumococci or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae")) AND ((MH "Vaccines") OR (MH "Immunization") OR TI (vaccine# or vaccination# or immunisation or immunization) OR AB (vaccine# or vaccination# or immunisation or immunization))</p>

	<p>OR</p> <p>(MH "Pneumococcal Vaccine") OR TI (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or "23valent") OR AB (heptavalent or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or pcv10 or "pcv 10" or "13valent" or "13 valent" or pcv13 or "pcv 13" or ppv23 or "ppv 23" or "23 valent" or "23valent")</p> <p>)</p> <p>AND</p> <p>(MH "Treatment Outcomes") OR TI (efficacy or effectiveness or effects or "immune response" or impact or "treatment outcome") OR AB (efficacy or effectiveness or effects or "immune response" or impact or "treatment outcome")</p> <p>AND</p> <p>((MH "Adult") OR (MH "Aged+") OR TI (adult# or elderly or elderlies) OR AB (adult# or elderly or elderlies))</p> <p>Limiters - Published Date: 20190401-20210218; Exclude MEDLINE records</p>
<p><b>Scopus</b> <b>(for WOS)</b></p>	<p>(<b>TITLE-ABS-KEY</b>("heptavalent" or "7 valent" or "7valent" or "pcv 7" or pcv7* or "10 valent" or "10valent" or "pcv10" or "pcv 10" or "13valent" or "13 valent" or "pcv13" or "pcv 13" or "ppv23" or "ppv 23" or "23 valent" or "23valent") OR (<b>TITLE-ABS-KEY</b>("vaccine\$" or "vaccination\$" or "immunisation" or "immunization") AND <b>TITLE-ABS-KEY</b>("pneumococcal" or "pneumococci" or "streptococcus pneumonie" or "streptococcus pneumoniae" or "s pneumoniae")))) AND <b>TITLE-ABS-</b></p>



	<p><b>KEY("adult\$" or "elderly" or "elderlies") AND TITLE-ABS-KEY("efficacy" or "effectiveness" or "effects" or "immune response" or "impact" or "treatment outcome")</b></p> <p>Limit April 2019 -</p>
Epistemonikos	<p>Search 1:</p> <p>(pneumococcal OR pneumococci OR "streptococcus pneumonie" OR "streptococcus pneumoniae" OR "s pneumoniae") AND (vaccine* OR vaccination* OR immunisation OR immunization) AND (efficacy OR effectiveness OR effects OR "immune response" OR impact OR "treatment outcome") AND (adult* OR elderly OR elderlies)</p> <p>– limited to 2019-2021</p> <p>Search 2:</p> <p>(heptavalent OR "7 valent" OR "7valent" OR "pcv 7" OR pcv7* OR "10 valent" OR "10valent" OR pcv10 OR "pcv 10" OR "13valent" OR "13 valent" OR pcv13 OR "pcv 13" OR ppv23 OR "ppv 23" OR "23 valent" OR "23valent") AND (efficacy OR effectiveness OR effects OR "immune response" OR impact OR "treatment outcome") AND (adult* OR elderly OR elderlies)</p> <p>– limited to 2019-2021</p>


Figure 1. PRISMA Study flow diagram



\*Berild 2020 is the publication for the Norwegian Public Health Institute (NIPH) systematic review of literature on pneumococcal vaccine effectiveness in adults conducted for the World Health Organization’s Strategic Advisory Group of Experts.

Figure 2. Pooled Vaccine Effectiveness Estimate of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Invasive Pneumococcal Disease in Adults Aged ≥ 60 Years: Observational studies, <5 years since vaccination

## Pooled Vaccine Effectiveness of PPSV23 against VT-IPD, all conditions



**Figure 3. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Invasive Pneumococcal Disease in Healthy Adults: Observational studies, <5 years since vaccination**

**Pooled Vaccine Effectiveness of PPSV23 against VT-IPD, exclude IC, youngest age group**




Figure 4. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Invasive Pneumococcal Disease in Adults Aged 65–74 years: Observational studies, <5 years since vaccination

### Pooled Vaccine Effectiveness of PPSV23 against VT-IPD, limited to adults aged 65-74 years




Figure 5. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Pneumococcal Pneumonia in Adults aged  $\geq 16$  Years: Observational studies,  $< 5$  years since vaccination

### Pooled Vaccine Effectiveness of PPSV23 against VT-Pneumococcal Pneumonia, $< 5$ Years of Vaccination




Figure 6. Pooled Vaccine Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against Vaccine-Type Pneumococcal Pneumonia in Adults Aged 65 – 74 Years: Observational studies, <5 years since vaccination

### Pooled Vaccine Effectiveness of PPSV23 against VT-Pneumococcal Pneumonia, Age 65-74 Years

